SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection

被引：52
|
作者：
Bell, Robert M. [1 ]
Yellon, Derek M. [1 ]
机构：
[1] UCL, Hatter Cardiovasc Inst, London WC1E 6HX, England
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2018年 / 6卷 / 06期
关键词：
OUTCOMES; EMPAGLIFLOZIN;
D O I：
10.1016/S2213-8587(17)30314-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：435 / 437
页数：4
相关论文
共 50 条
  • [1] Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
    Davide Margonato
    Giuseppe Galati
    Simone Mazzetti
    Rosa Cannistraci
    Gianluca Perseghin
    Alberto Margonato
    Andrea Mortara
    Heart Failure Reviews, 2021, 26 : 337 - 345
  • [2] Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
    Margonato, Davide
    Galati, Giuseppe
    Mazzetti, Simone
    Cannistraci, Rosa
    Perseghin, Gianluca
    Margonato, Alberto
    Mortara, Andrea
    HEART FAILURE REVIEWS, 2021, 26 (02) : 337 - 345
  • [3] SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection
    Felice Gragnano
    Fabrizia Terracciano
    Paolo Calabrò
    Journal of Cardiovascular Translational Research, 2024, 17 : 227 - 229
  • [4] SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection
    Gragnano, Felice
    Terracciano, Fabrizia
    Calabro, Paolo
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2024, 17 (01) : 227 - 229
  • [5] SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?
    Wilding, John
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (05): : 379 - 381
  • [6] Cardiovascular safety of SGLT2 inhibitors
    Gumprecht, Janusz
    CLINICAL DIABETOLOGY, 2016, 5 (02): : 62 - 65
  • [7] Cardiovascular benefit of SGLT2 inhibitors
    Mohebi, Reza
    Januzzi, James L.
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2022, 59 (03) : 142 - 155
  • [8] SGLT2 inhibitors in cardiovascular medicine
    Varzideh, Fahimeh
    Kansakar, Urna
    Santulli, Gaetano
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (04) : E67 - E68
  • [9] Cardiovascular effects of SGLT2 inhibitors
    Drexel, H.
    Saely, C. H.
    DIABETOLOGE, 2016, 12 (03): : 195 - 200
  • [10] SGLT2 inhibitors, hemodynamics, and kidney protection
    Ellison, David H.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2021, 321 (01) : F47 - F49
12345